Menu
← Oncology Approval Tracker
FDA DECISION ·
Keytruda + trastuzumab + chemotherapy
pembrolizumab + trastuzumab + fluoropyrimidine- and platinum-containing chemotherapy · Merck
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
This revised first-line accelerated approval for unresectable locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma required PD-L1 expression with a combined positive score of at least 1 on an FDA-approved test.
LAMPGEN ANALYSIS
Why it matters
The FDA narrowed the prior HER2-positive indication to a PD-L1-defined population.
What research teams should watch
Apply the PD-L1 combined positive score to the correct historical label date and document both HER2 and PD-L1 results.
PRIMARY RECORDS